24/7 Market News Snapshot 07 July, 2025 – KalVista Pharmaceuticals, Inc. Common Stock (NASDAQ:KALV)

July 7, 2025

DENVER, Colo., 07 July, 2025 (www.247marketnews.com) – (NASDAQ:KALV) are discussed in this article.
KalVista Pharmaceuticals, Inc. has achieved a significant milestone with the recent FDA approval of EKTERLY® (sebetralstat), marking it as the first oral treatment available for the acute management of hereditary angioedema (HAE) in patients aged 12 and older. This groundbreaking development not only transforms therapeutic options for HAE patients but also extends the promise of greater independence and prompt relief during acute episodes.

The company’s stock reflects this positive momentum, opening at $14.02 and enjoying a robust surge of 24.71%, currently trading at around $14.94 with a trading volume of 11.29 million shares. This surge indicates a strong investor sentiment bolstered by the recent approval news and heightened market interest.

CEO Ben Palleiko emphasized the importance of this approval, expressing gratitude to the dedicated teams and supportive networks that have contributed to this achievement. EKTERLY’s introduction significantly shifts the treatment landscape, moving patients away from traditional intravenous or subcutaneous therapies that often presented logistical hurdles and delayed treatment.

The efficacy of EKTERLY has been substantiated through the KONFIDENT phase 3 trial, the largest clinical study of HAE to date, demonstrating remarkable symptom relief and faster resolution of attacks compared to placebo. Patients involved in the study reported a median treatment initiation time of just 10 minutes following symptom onset, heralding a new era in HAE management.

In addition to EKTERLY, KalVista has launched the KalVista Cares™ program, designed to assist patients with personalized support concerning insurance navigation and ongoing medication adherence. As EKTERLY becomes available for prescription, KalVista Pharmaceuticals remains dedicated to advancing innovative therapies for individuals struggling with HAE, fostering hope and improved quality of life for many.

Related news for (KALV)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.